How India Exports Levothyroxine to the World

Levothyroxine sodium, a synthetic thyroid hormone, is extensively utilized in the United States for the treatment of hypothyroidism and other thyroid-related disorders. The FDA has approved numerous Abbreviated New Drug Applications (ANDAs) for generic formulations of levothyroxine tablets, indicating a well-established market presence. However, as of February 2026, the FDA has not approved generic versions of certain oral solution formulations, such as Ermeza, Thyquidity, and Tirosint-Sol. For instance, Ermeza, approved on April 29, 2022, remains without a generic counterpart due to existing patent protections.

The regulatory pathway for levothyroxine involves stringent bioequivalence requirements due to its narrow therapeutic index. Manufacturers must demonstrate consistent potency, stability, and bioavailability to gain FDA approval. Given that 63.6% of India's levothyroxine exports are destined for the U.S., and with 125 active Indian exporters, compliance with FDA regulations is paramount to maintain market access and ensure patient safety.

In the European Union and the United Kingdom, levothyroxine is subject to rigorous regulatory oversight. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require comprehensive data on quality, safety, and efficacy for marketing authorization. Notably, in October 2012, the EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Levothyroxine Alapis did not outweigh its risks, leading to the denial of marketing authorization in several EU Member States. (ema.europa.eu)

EU Good Manufacturing Practice (GMP) guidelines mandate that manufacturers adhere to high standards in production processes, quality control, and documentation. For Indian exporters, compliance with these GMP requirements is essential to access and sustain a presence in the European and UK markets.

Levothyroxine is listed in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, underscoring its critical role in global health. (who.int) This inclusion highlights the medication's importance in treating thyroid disorders worldwide. While the WHO Prequalification Programme primarily focuses on medicines for HIV, tuberculosis, malaria, and reproductive health, the listing of levothyroxine emphasizes its essential status.

Pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) provide detailed monographs for levothyroxine, ensuring consistency in quality and efficacy across different markets.

In India, levothyroxine is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, levothyroxine is subject to price controls to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) to monitor and regulate the export of pharmaceuticals, ensuring that domestic needs are met before permitting international shipments.

The patent landscape for levothyroxine varies by formulation and jurisdiction. For example, the oral solution formulation Ermeza is protected under U.S. Patent No. 9,345,772, issued on May 24, 2016, with an expiry date of February 27, 2035. This patent protection limits generic competition for specific formulations, influencing market dynamics and pricing strategies.

In September 2025, the WHO updated its Model List of Essential Medicines, reaffirming levothyroxine's inclusion and emphasizing its continued importance in global health. (who.int)

In November 2019, the EMA conducted a periodic safety update report single assessment (PSUSA) for levothyroxine, leading to variations in product information to enhance patient safety. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding levothyroxine, necessitating continuous monitoring and compliance by manufacturers and exporters to maintain market access and ensure patient safety.

Levothyroxine, a critical medication for thyroid disorders, relies heavily on Active Pharmaceutical Ingredients (APIs) sourced from India. However, India's API production is significantly dependent on Key Starting Materials (KSMs) imported from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a substantial supply chain vulnerability.

This dependency has led to supply chain disruptions in the past. For instance, in July 2018, environmental regulations in China resulted in the shutdown of several chemical plants, causing a ripple effect that impacted Indian pharmaceutical manufacturers reliant on Chinese KSMs. Such events underscore the fragility of the supply chain for essential medications like levothyroxine.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters account for 77.8% of levothyroxine exports, with MACLEODS PHARMACEUTICALS LTD alone contributing 32.9%. This high concentration poses a significant single-source risk, as any disruption within these key suppliers could severely impact global supply.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to boost domestic manufacturing and reduce import dependence. By March 2025, the scheme had led to import savings of ₹1,362 crore and the creation of domestic manufacturing capacity for 25 identified KSMs, DIs, and APIs. However, the effectiveness of this scheme in diversifying levothyroxine suppliers remains to be fully realized.

Geopolitical tensions and shipping disruptions have further exacerbated supply chain vulnerabilities. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical shipments; any instability in these regions can delay deliveries. Additionally, U.S.-China trade tensions have led to increased scrutiny and potential tariffs on pharmaceutical imports, affecting the cost and availability of essential drugs.

Regulatory bodies have noted these challenges. In October 2025, the U.S. Pharmacopeia highlighted the risks associated with concentrated KSM sourcing, emphasizing the need for supply chain diversification to prevent shortages of critical medications like levothyroxine.

• Diversify Supplier Base: Encourage the development of alternative suppliers for levothyroxine APIs and KSMs to reduce reliance on a limited number of manufacturers.

• Enhance Domestic Production: Strengthen initiatives like the PLI scheme to bolster domestic manufacturing capabilities for critical pharmaceutical ingredients.

• Monitor Geopolitical Developments: Establish a dedicated task force to assess and respond to geopolitical events that may impact the pharmaceutical supply chain.

• Strengthen Regulatory Compliance: Implement stringent quality control measures to ensure that all suppliers meet international standards, thereby reducing the risk of regulatory actions that could disrupt supply.

• Develop Strategic Reserves: Create stockpiles of essential medications like levothyroxine to buffer against potential supply chain disruptions.

RISK_LEVEL: HIGH